

AMENDMENT

U.S. Appln. No. 09/699,923

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-14. (Cancelled).

Claim 15. (Previously Presented) An *in vitro* method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem cells, progenitor cells, or hematopoietic stem and progenitor cells with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

Claim 16. (Previously Presented) An *in vitro* method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem cells, progenitor cells, or hematopoietic stem and progenitor cells with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand and GM-CSF in amounts sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

Claims 17-22. (Cancelled).

**AMENDMENT**

**U.S. Appln. No. 09/699,923**

Claim 23. (Previously Presented) The method according to claim 15 wherein the flt3-ligand is human flt3-ligand.

Claim 24. (Previously Presented) The method according to claim 16 wherein the flt3-ligand is human flt3-ligand.

Claim 25. (Previously Presented) The method according to claim 16 wherein the GM-CSF is human GM-CSF.

Claims 26-38. (Cancelled).